Total pharma industry M&A deals in Q1 2019 worth $127.86bn were announced in the US, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 962.3% over the previous quarter and a rise of 643.02% when compared with the last four-quarter average of $17.21bn.
The US held a 93.9% share of the global pharma industry M&A deal value that totalled $136.23bn in Q1 2019.
In terms of deal activity, the US recorded 54 deals during Q1 2019, marking a decrease of 27% over the previous quarter and a drop of 6.9% over the last four-quarter average.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The US pharma industry M&A deals in Q1 2019: Top deals
The top five pharma industry M&A deals accounted for 97.7% of the overall value during Q1 2019.
The combined value of the top five pharma industry M&A deals stood at $124.94bn, against the overall value of $127.86bn recorded for the quarter. The top announced pharma industry M&A deal tracked by GlobalData in Q1 2019 was Bristol-Myers Squibb‘s $89.54bn acquisition of Celgene.
In second place was the $21.4bn asset transaction with General Electric by Danaher and in third place was Eli Lilly’s $8bn acquisition of Loxo Oncology.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.